Sorafenib

製品コードS7397 別名:BAY 43-9006

Sorafenib化学構造

分子量(MW):464.82

Sorafenibは一種のRaf-1、 B-RafとVEGFR-2の多種キナーゼ阻害剤で,無細胞試験でIC50値が6 nM、22 nMと90 nMにそれぞれ分かれることです。

サイズ 価格(税別) 在庫  
JPY 24402.00 あり
JPY 44820.00 あり
JPY 111220.00 あり

文献中の使用例(62)

カスタマーフィードバック(9)

  • Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 μM), JNK inhibitor (16 μM), p38 inhibitor SB203580 (20 μM), and multikinase inhibitor sorafenib (10 μM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck.

    (A) were exposed to 200 uM gentamicin for various time periods. Immunoreactivity for phosphorylated JNK (green) and c-Jun (blue) in hair cells increased in a time-dependent manner. B. Hair cells from explants pre-treated with 500 nM sorafenib displayed a near complete inhibition of JNK activation at all time points analyzed.

    J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck.

  • Sorafenib in combination with metformin or the AMPK activator salicylate enhances AMPK activation. a, b, AMPK activation with the combination of sorafenib and metformin in LKB1 mutant KRAS mutant (A549 and H460) NSCLC cells (a), LKB1 wild-type KRAS mutant (H358) (b, left panel) or LKB1 mutant KRAS wild-type (H838) NSCLC cells (b, right panel). Cells were treated for 48 hr with sorafenib (1-3 uM), metformin (1–1.5 mM) or the combination of sorafenib and metformin with the same concentrations as were used for the individual treatments. c, AMPK activation with the combination of sorafenib and salicylate in LKB1 mutant KRAS mutant (A549 and H460) or LKB1 mutant KRAS wild-type (H838) NSCLC cells. Cells were treated for 48 hr with sorafenib (1–3 uM), salicylate (1–1.5 mM) or the combination of sorafenib and salicylate with the same concentrations as were used for the individual treatments. Cell lysates were harvested for western blot analysis and probed with the indicated antibodies.

    Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck.

    Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.

    Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck.

  • HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vivo. a Tumors from mice treated with PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H exo) were paraffin-embedded and sectioned, followed by staining of apoptotic cell by using TUNEL assays.

    J Exp Clin Cancer Res, 2016, 35(1):159. Sorafenib purchased from Selleck.

    Sorafenib and PX-866 interact to suppress tumor growth in vivo. Mice were PO administered vehicle diluent, sorafenib (25 mg/kg), PX-866 (2 mg/kg), or the drug combination QD for 3 days. Animals were monitored daily and tumor volume determined every fifth day. Tumors from animals were isolated at day 15 and fixed, sectioned (10-um), and stained against proliferation (Ki67 staining), phospho-ERK1/2 and phospho-AKT staining, the levels of tumor cell apoptosis/cleaved caspase 3, as well as with H&E and 4′,6-diamidino-2-phenylindole (DAPI).

    Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck.

  • Effects of sorafenib or sunitinib on LicA-induced cell death, ER stress responses, PLCc1, Ca2+, and ROS in HepG2 cells. HepG2 cells were pretreated with sorafenib or sunitinib for 1 h, then treated with LicA or TG for 1 h (for P-eIF2a and P-PLCc1) or 24 h (for CHOP, ATF6a(p90), and caspase-4). The cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6a(p90), caspase-4(C), P-eIF2a, and b-actin.

    Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck.

    PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck.

  • (C) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in HUH-7 and R-HUH-7 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (D) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in SK-HEP-1 and R-SK-HEP-1 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (E) HUH-7 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. (F) SK-HEP-1 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. Data were expressed as mean ± standard deviation of each experiment in triplicate. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. Sorafenib purchased from Selleck.

製品安全説明書

Raf阻害剤の選択性比較

生物活性

製品説明 Sorafenibは一種のRaf-1、 B-RafとVEGFR-2の多種キナーゼ阻害剤で,無細胞試験でIC50値が6 nM、22 nMと90 nMにそれぞれ分かれることです。
ターゲット
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
体外試験

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NWLnS4t7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMECwNFA{ODNizszN NWTWc2JtW0GQR1XS
MONO-MAC-6 M{HiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLMfZpkUUN3ME2wMlAxPDF6IN88US=> Mly4V2FPT0WU
ALL-PO M3ixSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2S2bmlEPTB;MD6wN|E5PCEQvF2= NX3jPFd1W0GQR1XS
NKM-1 M2[0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPkTWM2OD1yLkC3OFE3KM7:TR?= NGXacHNUSU6JRWK=
CGTH-W-1 NHLwOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz4TWM2OD1yLkK1NFIzKM7:TR?= MVPTRW5ITVJ?
BB65-RCC M2Prd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrUTWM2OD1yLkS3NFc{KM7:TR?= MX;TRW5ITVJ?
NOS-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\iTWM2OD1yLkW2N|Yh|ryP NUfQW4tCW0GQR1XS
SH-4 MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwNkW2NVMh|ryP NFzNOFBUSU6JRWK=
HOP-62 NEHafHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2mwfmlEPTB;MD64OVA5QCEQvF2= MX3TRW5ITVJ?
HCC2998 NGi2e2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XQTGlEPTB;MD64PFgyQCEQvF2= MnjhV2FPT0WU
GDM-1 M2nHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwOUC2PVgh|ryP Mk[0V2FPT0WU
KM12 Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFwMEKwPVgh|ryP MXnTRW5ITVJ?
LB2518-MEL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwMkC4NFkh|ryP MoLkV2FPT0WU
NCI-H1436 MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\CbGtKSzVyPUGuNlE3PzhizszN MkTDV2FPT0WU
EM-2 MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInRcmhKSzVyPUGuN|U2PzhizszN M17QOXNCVkeHUh?=
LAMA-84 NFmx[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFwM{e2OFgh|ryP Mk\ZV2FPT0WU
KG-1 M2jieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W2c2lEPTB;MT60O|k{PSEQvF2= NITzSYJUSU6JRWK=
A388 M2TVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j5O2lEPTB;MT61PVE3PSEQvF2= NFfN[XlUSU6JRWK=
no-10 NFXoZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn6e5hsUUN3ME2xMlYyPzJ4IN88US=> MWTTRW5ITVJ?
SF126 M2j1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnyWmFKSzVyPUGuOlM5OTJizszN MYTTRW5ITVJ?
MEG-01 M{TqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;MTWM2OD1zLkiwPVgh|ryP MYjTRW5ITVJ?
A3-KAW NXzMZXNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHix[|hKSzVyPUGuPFg1OiEQvF2= M3PmeHNCVkeHUh?=
D-247MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rFR2lEPTB;Mj6xOFQ5KM7:TR?= M3L3ZnNCVkeHUh?=
OVCAR-4 NH;nc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq0TWM2OD1{LkKxN|k{KM7:TR?= NYHIe|BqW0GQR1XS
NCI-SNU-1 NITTRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTkTWM2OD1{LkOxOlIh|ryP NYnCUZlVW0GQR1XS
NCI-H2171 M{DIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXyTWM2OD1{LkO5O|Y1KM7:TR?= M2fadnNCVkeHUh?=
SIG-M5 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPXeG9MUUN3ME2yMlQzOjR{IN88US=> NHL4eYdUSU6JRWK=
BE-13 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDjTWM2OD1{Lk[5OlA6KM7:TR?= MmWwV2FPT0WU
K052 NI\OS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljxTWM2OD1{Lke0OlE3KM7:TR?= MofXV2FPT0WU
L-540 NV\uboROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJwN{W3PFkh|ryP NV3oOGk2W0GQR1XS
KMOE-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vLRmlEPTB;Mj64NVM2KM7:TR?= NV;rO5V1W0GQR1XS
MFH-ino NHvOfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP1PIFKSzVyPUKuPVIyQDVizszN MVPTRW5ITVJ?
HL-60 NX3VXWpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTETWM2OD1|LkC2Nlk6KM7:TR?= MVzTRW5ITVJ?
HCC2218 NVrtRoQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q3cmlEPTB;Mz6xNlAxOyEQvF2= M1HPNHNCVkeHUh?=
TE-5 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;Sb2lEPTB;Mz6xN|E3OiEQvF2= M2PLb3NCVkeHUh?=
MZ1-PC M1nXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX3R21yUUN3ME2zMlQ4PTB7IN88US=> NX3RZXo3W0GQR1XS
MRK-nu-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITzR|ZKSzVyPUOuOlE1PjhizszN MX;TRW5ITVJ?
MZ7-mel Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTSUo5KSzVyPUOuOlYxQTlizszN NUflZZVtW0GQR1XS
BC-1 Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTNwN{SwNkDPxE1? NF;IeZlUSU6JRWK=
ST486 NIrqSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDnWmo3UUN3ME2zMlg{Pjd|IN88US=> MX;TRW5ITVJ?
KS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTNwOEixPVgh|ryP M4KyPXNCVkeHUh?=
SK-NEP-1 NHXRcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XXOmlEPTB;ND6xOlgyPSEQvF2= NHPmfXFUSU6JRWK=
BC-3 NVXLbFNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3u[45KSzVyPUSuNlM{QTFizszN MkPyV2FPT0WU
NCI-H1581 NUXCT4FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i5eGlEPTB;ND6yPFc6QCEQvF2= M4PnZXNCVkeHUh?=
MHH-PREB-1 NYrRbldHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH5d4VJUUN3ME20MlQxPDh2IN88US=> NEDOSJhUSU6JRWK=
NOMO-1 NX3hNJJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTRwNEi5NFUh|ryP M{PmUHNCVkeHUh?=
QIMR-WIL NWHvWlNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\POpNKSzVyPUWuNFczQTRizszN MXrTRW5ITVJ?
SF539 NH25[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvQTWM2OD13LkGzNlI4KM7:TR?= NVHVfW5oW0GQR1XS
TE-12 NHXy[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXvTWM2OD13LkK0PVI6KM7:TR?= NEPQOpVUSU6JRWK=
NCI-H510A NGXNUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojtTWM2OD13LkSxOlg2KM7:TR?= NYTSUG86W0GQR1XS
JAR MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDCUXlKSzVyPUWuOVA5OjRizszN NX\DS2NnW0GQR1XS
no-11 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDNb3ZtUUN3ME21Mlc{PTZ6IN88US=> MoW3V2FPT0WU
BV-173 M3fYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LF[GlEPTB;NT65OVY5OiEQvF2= MX7TRW5ITVJ?
SR MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTZwMEC2O|gh|ryP NHHkPZNUSU6JRWK=
MOLT-16 NIjvU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHNNXZbUUN3ME22MlI2OjZ4IN88US=> NF3qSGZUSU6JRWK=
MZ2-MEL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjETWM2OD14LkOxPFM6KM7:TR?= MUTTRW5ITVJ?
SW954 NXL1O2J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTZwNEW4OlYh|ryP MXHTRW5ITVJ?
ML-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TmfGlEPTB;Nj61Nlg1QSEQvF2= NWGwNJFPW0GQR1XS
OCI-AML2 NYnscmo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT2TWM2OD14Lk[xNFYzKM7:TR?= NH7UNYRUSU6JRWK=
SIMA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\HS3hGUUN3ME23MlAxOTBzIN88US=> MXLTRW5ITVJ?
DOHH-2 NIq1eHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnJRWxKSzVyPUeuNFU3PzZizszN MXXTRW5ITVJ?
697 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PtcmlEPTB;Nz6wOVk5QSEQvF2= NXS4[IlvW0GQR1XS
NB1 NX\UZoFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnvb2E4UUN3ME23MlQxPDB5IN88US=> MnHHV2FPT0WU
D-392MG NHvvemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[wN2lEPTB;Nz62NlY3OyEQvF2= MorhV2FPT0WU
ES8 NUXMRXJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTdwN{[1NFMh|ryP MWrTRW5ITVJ?
RPMI-8226 NWfGbo1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;vN2lEPTB;Nz64OFUyOSEQvF2= MUXTRW5ITVJ?
IST-MEL1 NVe0[oRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYWwVXpvUUN3ME24MlQxODB{IN88US=> MnT0V2FPT0WU
NB14 NXTGb2ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XofmlEPTB;OD62N|E{OyEQvF2= M2XR[XNCVkeHUh?=
HD-MY-Z M4H6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\weVFKSzVyPUiuOlM4PDZizszN MYXTRW5ITVJ?
TE-10 NWP6NmxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\YTWM2OD16Lke2N|U{KM7:TR?= Mo\NV2FPT0WU
LC-1F M4DVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS4PGZKSzVyPUmuNVA5OzRizszN NFXadHlUSU6JRWK=
OS-RC-2 M2TUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\rTmJLUUN3ME25MlEyOjR|IN88US=> MnTUV2FPT0WU
NCI-SNU-16 Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P6R2lEPTB;OT6yNVAzPiEQvF2= NEW1R2ZUSU6JRWK=
SHP-77 NFfMNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTlwN{G2OlIh|ryP M1nFTHNCVkeHUh?=
A4-Fuk M1nrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3hTWM2OD17Lke1OlEh|ryP M4fUXXNCVkeHUh?=
NB6 M2ruWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf4S4tKSzVyPUmuO|YxOjlizszN M4HpPHNCVkeHUh?=
JiyoyeP-2003 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnPTWM2OD1zMD60O|Q2KM7:TR?= NVnDOWxtW0GQR1XS
DMS-114 NGrNc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzxfopKSzVyPUGwMlU1PDFizszN MmfKV2FPT0WU
NB7 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3OxTWlEPTB;MUCuO|UzPiEQvF2= NEHvSWtUSU6JRWK=
NCI-H747 NIi4[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHSWGhqUUN3ME2xNU4yOjF4IN88US=> NVzEZoRtW0GQR1XS
HH M1\GfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13VRmlEPTB;MUGuN|g4PiEQvF2= MojjV2FPT0WU
EW-18 M4r4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PXNmlEPTB;MUGuPVA1PCEQvF2= MV3TRW5ITVJ?
CHP-126 Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTiRmpKSzVyPUGxMlk4OzhizszN MWXTRW5ITVJ?
NTERA-S-cl-D1 MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW0TWM2OD1zMj6wNlc5KM7:TR?= MYDTRW5ITVJ?
DEL NXn6W3pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF{LkC5PFUh|ryP MYPTRW5ITVJ?
LU-139 NFHLTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\rNmlEPTB;MUKuOVQyOyEQvF2= M4Ljd3NCVkeHUh?=
P30-OHK MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fyOmlEPTB;MUKuOVQ4QSEQvF2= NIfPeG1USU6JRWK=
NCI-H1522 NH7veWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPYOG9KSzVyPUGyMlc1PiEQvF2= MWnTRW5ITVJ?
NCI-H1299 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfVdJJlUUN3ME2xN{4zQTFzIN88US=> NYr5dldiW0GQR1XS
UACC-257 M3jqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnW[XdMUUN3ME2xN{42OTJ4IN88US=> NUXPcZBLW0GQR1XS
Calu-6 M1ziSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HIV2lEPTB;MUOuOlA1PiEQvF2= NUPXRmZ2W0GQR1XS
NCI-H1882 NXzuSFNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTF|Lki1OVUh|ryP MW\TRW5ITVJ?
BB30-HNC MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfTclFRUUN3ME2xOE4xPjB7IN88US=> NGfGN2dUSU6JRWK=
ES1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFL3ZopKSzVyPUG0MlE2PTFizszN M1Pz[XNCVkeHUh?=
NCI-H1694 NVP4eVF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjoblhKSzVyPUG0MlQ5OTFizszN M4jlc3NCVkeHUh?=
IST-SL1 NI\0ZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nTS2lEPTB;MUSuPVYyPiEQvF2= M3zWd3NCVkeHUh?=
ECC4 NIHG[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPqdGxkUUN3ME2xOU4xPTV6IN88US=> NVH6eYd[W0GQR1XS
MDA-MB-134-VI M4Hq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2npWmlEPTB;MUWuOFE{OSEQvF2= MXLTRW5ITVJ?
SCH Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG4[5dFUUN3ME2xOU41PzJ6IN88US=> MU\TRW5ITVJ?
SK-N-FI NHzZZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXu4bIZ7UUN3ME2xOU43PTN2IN88US=> Mnr6V2FPT0WU
HDLM-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTF4LkC3NVQh|ryP NX;0N5p{W0GQR1XS
Ramos-2G6-4C10 M{fZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF4LkGyPVch|ryP MmOwV2FPT0WU
EW-24 M3r3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrZSo9KUUN3ME2xOk4yPjZzIN88US=> NH\Vb4NUSU6JRWK=
NCI-H2141 M2C0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PBZmlEPTB;MU[uNVg6KM7:TR?= MkfIV2FPT0WU
LC4-1 NFrVUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPV[pBKSzVyPUG2MlYyOTlizszN MYPTRW5ITVJ?
HT-144 Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF5LkCwOkDPxE1? MXzTRW5ITVJ?
SK-MEL-1 NX[2TJNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn24TWM2OD1zNz6wNFczKM7:TR?= NULBNWJXW0GQR1XS
SCC-15 NYTkOI01T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF5LkG2N|gh|ryP NVLjNmY6W0GQR1XS
C8166 NFPVRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTF5Lk[4N|Mh|ryP M1\1[HNCVkeHUh?=
GOTO MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPuU5V6UUN3ME2xO{45OzR2IN88US=> Ml6xV2FPT0WU
COR-L279 MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzuSpFZUUN3ME2xPE4yOzZ{IN88US=> NUO1W|k6W0GQR1XS
K-562 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF6LkexOFMh|ryP MXzTRW5ITVJ?
ES3 M4HuXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF6LkiwOFEh|ryP M13JZXNCVkeHUh?=
LU-165 M{jnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\mSWNKSzVyPUG5MlcxODhizszN NEX1eFhUSU6JRWK=
KM-H2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\WTWM2OD1{MD6zNVg1KM7:TR?= NH;QO3dUSU6JRWK=
RL MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zr[2lEPTB;MkCuPVY6OiEQvF2= NVrOPFdmW0GQR1XS
EW-3 MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJzLkG4PFkh|ryP MkLjV2FPT0WU
A101D MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LHe2lEPTB;MkGuN|c2OiEQvF2= NGfqVlRUSU6JRWK=
HUTU-80 NFLaNW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnFR|ZPUUN3ME2yNU4{QTR4IN88US=> MmLtV2FPT0WU
NCI-H23 NVW5RpBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme3TWM2OD1{MT6zPVkzKM7:TR?= M{LhUnNCVkeHUh?=
PF-382 M1Lkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJzLkS0NFMh|ryP M2\kfHNCVkeHUh?=
LB373-MEL-D NEHhdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{KybGlEPTB;MkGuOVYyPSEQvF2= Mk\MV2FPT0WU
TE-8 NVHOfoRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rWbmlEPTB;MkGuOlM6PCEQvF2= NEXjNGVUSU6JRWK=
TE-9 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf0PYxWUUN3ME2yNU45PTF|IN88US=> NWHFOWs4W0GQR1XS
Daudi M3\re2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXFbGRtUUN3ME2yNU46OzB2IN88US=> M3u3OHNCVkeHUh?=
D-542MG M172ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInnSoRKSzVyPUKyMlAzPTZizszN Moi0V2FPT0WU
U-698-M NXewb2ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrBTFVKSzVyPUKyMlQ3ODNizszN Mn7HV2FPT0WU
ES6 NUPrcJY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LrS2lEPTB;MkKuO|M3PiEQvF2= MmixV2FPT0WU
DU-4475 MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJ|Lki4PVch|ryP MWrTRW5ITVJ?
ECC12 NVzTbItCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEO3OYlKSzVyPUK0MlI5ODNizszN NFf5R5ZUSU6JRWK=
C2BBe1 MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfJTWM2OD1{ND6zNlM6KM7:TR?= NV6zfYl[W0GQR1XS
IST-SL2 MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\HfnVKSzVyPUK0MlQ{PjJizszN MYDTRW5ITVJ?
DJM-1 MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[4TWM2OD1{ND61NlIyKM7:TR?= MkTJV2FPT0WU
DMS-153 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJ2Lki2NVQh|ryP NInoUGNUSU6JRWK=
NB13 MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;hXGNKSzVyPUK1MlAzPjVizszN NUTJNWtIW0GQR1XS
SK-N-DZ NFu4RWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fIZWlEPTB;Mk[uN|QyPCEQvF2= MkPxV2FPT0WU
COR-L88 M1;TVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4GwfmlEPTB;Mk[uOVc6PiEQvF2= MmD6V2FPT0WU
LU-65 MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJ4Lki1N|Uh|ryP NGXWPYpUSU6JRWK=
TGBC1TKB MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\1W4tKSzVyPUK2Mlk5OjhizszN MkXvV2FPT0WU
THP-1 MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPSNWRKSzVyPUK3MlIyPDFizszN M3n6OnNCVkeHUh?=
ONS-76 NWj3S4psT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj3cWw3UUN3ME2yO{4{OzJizszN M4TFNXNCVkeHUh?=
LC-2-ad NHryZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVizTWV3UUN3ME2yO{43OjNzIN88US=> M37kSHNCVkeHUh?=
EW-13 NHLKbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPDNodYUUN3ME2yPU4yPzR4IN88US=> M2PyS3NCVkeHUh?=
MS-1 NUj4OlFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2raVWlEPTB;M{CuO|I4QCEQvF2= M1[4OXNCVkeHUh?=
NCI-H2227 NFLxNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TpeWlEPTB;M{CuPVgxPiEQvF2= NXvpOIJPW0GQR1XS
LXF-289 NHm2S4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXwTWM2OD1|MT60OFkzKM7:TR?= M1\YS3NCVkeHUh?=
MC116 NUP4dIl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHpOmZKSzVyPUOyMlA5OjZizszN M2\GfnNCVkeHUh?=
EVSA-T NVzIdldiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PaPGlEPTB;M{KuNlU5PSEQvF2= NX7SU5RGW0GQR1XS
CTB-1 Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\TTWM2OD1|Mz6xNVAyKM7:TR?= M4LG[3NCVkeHUh?=
COLO-320-HSR NIfk[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zSUWlEPTB;M{OuNVYxOyEQvF2= NHGwepFUSU6JRWK=
NCI-H2196 NXHkRmJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHNZo1oUUN3ME2zN{4zPTV5IN88US=> NF7rTXVUSU6JRWK=
LB2241-RCC MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfvTWM2OD1|Mz6zNVM2KM7:TR?= M17tTnNCVkeHUh?=
LS-513 NGfnZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN|Lki2N|gh|ryP MlvWV2FPT0WU
LP-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\yTFBNUUN3ME2zN{46QTV4IN88US=> MlvEV2FPT0WU
A253 NGnCV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PrR2lEPTB;M{SuNlI6PiEQvF2= MYHTRW5ITVJ?
SK-MM-2 M3npSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mki1TWM2OD1|ND65OFUyKM7:TR?= NXjO[nRIW0GQR1XS
NCI-H1963 MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPDZY1tUUN3ME2zOU4{ODd{IN88US=> Mn;zV2FPT0WU
MMAC-SF NELaZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K5SmlEPTB;M{WuPFc5PSEQvF2= M3fNVHNCVkeHUh?=
LB831-BLC MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInjdXRKSzVyPUO2MlA3PTRizszN NGO0PYFUSU6JRWK=
WSU-NHL NYnJXVFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrU[3M3UUN3ME2zOk4yPjRizszN M4jXZXNCVkeHUh?=
CESS MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DGSmlEPTB;M{[uNlg1QCEQvF2= MX3TRW5ITVJ?
NEC8 NWi1emJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PXdmlEPTB;M{[uOVg{PSEQvF2= NHW4WG5USU6JRWK=
KNS-42 M{TK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHjclh7UUN3ME2zO{4yOjN5IN88US=> M{nkSnNCVkeHUh?=
MHH-CALL-2 M1fEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHPNnNKSzVyPUO3MlE5OjFizszN MYfTRW5ITVJ?
K5 M3noRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjZUY9KSzVyPUO4MlQ{KM7:TR?= NYHvd4hDW0GQR1XS
CP66-MEL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTN7LkC3N|Mh|ryP NHXKZ4tUSU6JRWK=
OPM-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\kTWM2OD1|OT64OFMzKM7:TR?= M1TBeHNCVkeHUh?=
IST-MES1 NX3pU|BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzyNXNSUUN3ME20NE4{ODl4IN88US=> NXzLPVdwW0GQR1XS
EC-GI-10 M4L6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ThZ2lEPTB;NEGuOVgxPSEQvF2= MWLTRW5ITVJ?
CTV-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTsO4EyUUN3ME20Nk45PDB4IN88US=> NHnZd4lUSU6JRWK=
DG-75 MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe3[ppKSzVyPUSzMlc2QTVizszN MmfnV2FPT0WU
KNS-81-FD Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC2TWM2OD12NT60NFU5KM7:TR?= M3PsWHNCVkeHUh?=
NCI-H82 Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTR3LkW3OVgh|ryP MUHTRW5ITVJ?
RPMI-8866 NV\PeGhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\mVox3UUN3ME20Ok4yQDd|IN88US=> Mn35V2FPT0WU
ACN M{L3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTR4LkSzOEDPxE1? NVTUTHBDW0GQR1XS
NCI-H1395 MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTR4LkS3OVYh|ryP MnjiV2FPT0WU
NCI-H209 NE[zO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;ifWlEPTB;NEeuNVQxPSEQvF2= NV3SeGp5W0GQR1XS
TGW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXDd2RnUUN3ME20PU4xPzlzIN88US=> NEXnTohUSU6JRWK=
NCI-H748 MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPXTWM2OD12OT60O|U{KM7:TR?= NXjqW2Z[W0GQR1XS
EKVX NHTR[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTR7Lk[2Nlgh|ryP NXzLTHd{W0GQR1XS

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
細胞試験:

[1]

+ 展開
  • 細胞株: MDA-MB-231, and HAoSMC
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • 製剤: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • 投薬量: ~60 mg/kg
  • 投与方法: Orally once daily
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 63 mg/mL (135.53 mM) warming
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
5% DMSO+45% PEG 400+ddH2O
3mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 464.82
化学式

C21H16ClF3N4O3

CAS No. 284461-73-0
保管
別名 BAY 43-9006

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00727233 Completed Neurofibromatosis Type I|Plexiform Neurofibroma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 8, 2008 Phase 1
NCT02989870 Not yet recruiting HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer H. Lee Moffitt Cancer Center and Research Institute|National Comprehensive Cancer Network April 30, 2017 Phase 1
NCT01445080 Completed Leukemia|With AML and FLT3-ITD Mutations National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 23, 2006 Phase 1
NCT01434602 Recruiting Brain Tumor|Glioblastoma|Anaplastic Glioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 21, 2015 Phase 1|Phase 2
NCT02988440 Not yet recruiting Hepatocellular Carcinoma Novartis Pharmaceuticals|Novartis May 2017 Phase 1
NCT03037437 Not yet recruiting Hepatocellular Cancer The University of Texas Health Science Center at San Antonio January 2017 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Raf信号経路図

相関Raf製品

Tags: Sorafenibを買う | Sorafenib ic50 | Sorafenib供給者 | Sorafenibを購入する | Sorafenib費用 | Sorafenib生産者 | オーダーSorafenib | Sorafenib化学構造 | Sorafenib分子量 | Sorafenib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID